Radium-223 for the treatment of castration-resistant prostate cancer
The vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases. Bone metastases are a source of significant morbidity and affect quality of life in these patients. Several bone-targeting agents are approved for the treatment of bone metastases in p...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | |
| التنسيق: | article |
| منشور في: |
2015
|
| الوصول للمادة أونلاين: | http://hdl.handle.net/10725/6261 http://dx.doi.org/10.2147/OTT.S44291 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445785/ |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513478949076993 |
|---|---|
| author | El-Amm, Joelle |
| author2 | Aragon-Ching, Jeanny B. |
| author2_role | author |
| author_facet | El-Amm, Joelle Aragon-Ching, Jeanny B. |
| author_role | author |
| dc.creator.none.fl_str_mv | El-Amm, Joelle Aragon-Ching, Jeanny B. |
| dc.date.none.fl_str_mv | 2015 2017-09-25T08:06:16Z 2017-09-25T08:06:16Z 2017-09-25 |
| dc.identifier.none.fl_str_mv | 1178-6930 http://hdl.handle.net/10725/6261 http://dx.doi.org/10.2147/OTT.S44291 El-Amm, J., & Aragon-Ching, J. B. (2015). Radium-223 for the treatment of castration-resistant prostate cancer. OncoTargets and therapy, 8, 1103. http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445785/ |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | OncoTargets and Therapy |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Radium-223 for the treatment of castration-resistant prostate cancer |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | The vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases. Bone metastases are a source of significant morbidity and affect quality of life in these patients. Several bone-targeting agents are approved for the treatment of bone metastases in prostate cancer, including bisphosphonates, denosumab, and radiopharmaceuticals. Radium-223 is a novel first-in-class alpha-emitting radiopharmaceutical that has been approved for treatment of patients with mCRPC with bone metastases. Radium-223 delivers cytotoxic radiation to the sites of bone metastases and offers the advantage of minimal myelosuppression. The landmark Phase III ALSYMPCA trial demonstrated that, in addition to providing bone-related palliation, radium-223 can also prolong overall survival in patients with mCRPC with bone metastases in the absence of visceral metastases and in the absence of lymphadenopathy greater than 3 cm. Ongoing trials will further elucidate its use in sequence or combination with other available therapies for mCRPC. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_fc78eda67bc5269bdfbe668aed9e47f5 |
| identifier_str_mv | 1178-6930 El-Amm, J., & Aragon-Ching, J. B. (2015). Radium-223 for the treatment of castration-resistant prostate cancer. OncoTargets and therapy, 8, 1103. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/6261 |
| publishDate | 2015 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Radium-223 for the treatment of castration-resistant prostate cancerEl-Amm, JoelleAragon-Ching, Jeanny B.The vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases. Bone metastases are a source of significant morbidity and affect quality of life in these patients. Several bone-targeting agents are approved for the treatment of bone metastases in prostate cancer, including bisphosphonates, denosumab, and radiopharmaceuticals. Radium-223 is a novel first-in-class alpha-emitting radiopharmaceutical that has been approved for treatment of patients with mCRPC with bone metastases. Radium-223 delivers cytotoxic radiation to the sites of bone metastases and offers the advantage of minimal myelosuppression. The landmark Phase III ALSYMPCA trial demonstrated that, in addition to providing bone-related palliation, radium-223 can also prolong overall survival in patients with mCRPC with bone metastases in the absence of visceral metastases and in the absence of lymphadenopathy greater than 3 cm. Ongoing trials will further elucidate its use in sequence or combination with other available therapies for mCRPC.PublishedN/A2017-09-25T08:06:16Z2017-09-25T08:06:16Z20152017-09-25Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1178-6930http://hdl.handle.net/10725/6261http://dx.doi.org/10.2147/OTT.S44291El-Amm, J., & Aragon-Ching, J. B. (2015). Radium-223 for the treatment of castration-resistant prostate cancer. OncoTargets and therapy, 8, 1103.http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.phphttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445785/enOncoTargets and Therapyinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/62612021-03-19T10:03:25Z |
| spellingShingle | Radium-223 for the treatment of castration-resistant prostate cancer El-Amm, Joelle |
| status_str | publishedVersion |
| title | Radium-223 for the treatment of castration-resistant prostate cancer |
| title_full | Radium-223 for the treatment of castration-resistant prostate cancer |
| title_fullStr | Radium-223 for the treatment of castration-resistant prostate cancer |
| title_full_unstemmed | Radium-223 for the treatment of castration-resistant prostate cancer |
| title_short | Radium-223 for the treatment of castration-resistant prostate cancer |
| title_sort | Radium-223 for the treatment of castration-resistant prostate cancer |
| url | http://hdl.handle.net/10725/6261 http://dx.doi.org/10.2147/OTT.S44291 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445785/ |